Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECONNECT Study 302: Bremelanotide for HSDD
NCT02338960Phase 3Completed
- Sponsor
- Palatin Technologies, Inc.
- Start
- Jan 2015
- Primary completion
- Aug 2016
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in hypoactive sexual desire disorder (HSDD) comparing Bremelanotide with Placebo (2 arms). Primary endpoints: Female Sexual Function Index - Desire Domain (Q1 and Q2) at 52 weeks and Female Sexual Distress Scale-Desire/Arousal/Orgasm Item 13 at 52 weeks. Started Jan 2015; status: completed.
02
Drugs
bremelanotide
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT02338960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338960.